JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coffield, J. A.
Right arrow Articles by Simpson, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coffield, J. A.
Right arrow Articles by Simpson, L. L.

Vol. 280, Issue 3, 1489-1498, 1997

In Vitro Characterization of Botulinum Toxin Types A, C and D Action on Human Tissues: Combined Electrophysiologic, Pharmacologic and Molecular Biologic Approaches1

J. A. Coffield, N. Bakry, R.-d. Zhang, J. Carlson, L. G. Gomella and L. L. Simpson

From the Departments of Medicine and Pharmacology (J.A.C., N.B., R.-d.Z., and L.L.S.), Obstetrics-Gynecology (J.C.) and Urology (L.G.G.), Jefferson Medical College, Philadelphia, Pennsylvania

Human exposure to botulinum toxin typically occurs in two settings: 1) as an etiologic agent in the disease botulism and 2) as a therapeutic agent for the treatment of dystonia. Epidemiologic studies on botulism suggest that the human nervous system is susceptible to five toxin serotypes (A, B, E, F and G) and resistant to two (C and D). In the past, these epidemiologic findings have been used as the basis for selecting serotypes that should be tested as therapeutic agents for dystonia. Epidemiologic data have been utilized because there are no studies of botulinum neurotoxin action on isolated human nerves. In the present study, electrophysiologic techniques were used to monitor toxin effects on neuromuscular transmission in surgically excised human pyramidalis muscles, ligand binding studies were done to detect and characterize toxin receptors in human nerve membrane preparations, and molecular biologic techniques were used to isolate and sequence a human gene that encodes a substrate for botulinum neurotoxin. The results demonstrated that stable resting membrane potentials (-61.5 mV; S.E.M. ± 0.7) were maintained in individual fibers of pyramidalis muscle for up to 6 hr at 33°C. The rate of spontaneous miniature endplate potentials was low in physiologic solution (0.14 sec-1) but increased in response to elevations in extracellular potassium concentration. In keeping with epidemiologic findings, botulinum toxin type A (10-8 M) paralyzed transmission in human preparations (ca. 90 min). In contrast to epidemiologic findings, serotype C (10-8 M) also paralyzed human tissues (ca. 65 min). Iodinated botulinum toxin displayed high-affinity binding to receptors in human nerve membrane preparations (serotype A high-affinity site: Kd = 0.3 nM, Bmax = 0.78 pmol/mg protein; serotype C high-affinity site: Kd = 1.96 nM, Bmax = 8.9 pmol/mg protein). In addition, the human nervous system was found to encode polypeptides that are substrates for botulinum neurotoxin types A (synaptosomal-associated protein of Mr 25,000) and C (syntaxin 1A). These data have important implications bearing on: 1) the development and administration of vaccines against botulism and 2) the testing of toxin serotypes for the treatment of dystonia.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
MicrobiologyHome page
Y. Jin, Y. Takegahara, Y. Sugawara, T. Matsumura, and Y. Fujinaga
Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C
Microbiology, January 1, 2009; 155(1): 35 - 45.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Tsukamoto, T. Kohda, M. Mukamoto, K. Takeuchi, H. Ihara, M. Saito, and S. Kozaki
Binding of Clostridium botulinum Type C and D Neurotoxins to Ganglioside and Phospholipid: NOVEL INSIGHTS INTO THE RECEPTOR FOR CLOSTRIDIAL NEUROTOXINS
J. Biol. Chem., October 21, 2005; 280(42): 35164 - 35171.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. B. Maksymowych and L. L. Simpson
Structural Features of the Botulinum Neurotoxin Molecule That Govern Binding and Transcytosis across Polarized Human Intestinal Epithelial Cells
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 633 - 641.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Kalandakanond and J. A. Coffield
Cleavage of Intracellular Substrates of Botulinum Toxins A, C, and D in a Mammalian Target Tissue
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 749 - 755.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
J. A. Coffield, N. M. Bakry, A. B. Maksymowych, and L. L. Simpson
Characterization of a Vertebrate Neuromuscular Junction That Demonstrates Selective Resistance to Botulinum Toxin
J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1509 - 1516.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
A. B. Maksymowych and L. L. Simpson
Binding and Transcytosis of Botulinum Neurotoxin by Polarized Human Colon Carcinoma Cells
J. Biol. Chem., August 21, 1998; 273(34): 21950 - 21957.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. L. Simpson, A. B. Maksymowych, and S. Hao
The Role of Zinc Binding in the Biological Activity of Botulinum Toxin
J. Biol. Chem., July 13, 2001; 276(29): 27034 - 27041.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.